Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study conducted at Detroit’s Henry Ford Hospital.
Endometrial cancer affects more than 45,000 women a year in the United States, usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known preventive medication for women at high risk of developing it.
"The results of the study suggest that use of low bone density medications may have a protective effect on endometrial cancer, or that women who take them get a less-aggressive cancer," said Sharon Hensley Alford, PhD, lead author of the study, and a researcher in public health services at Henry Ford Hospital.
The classification for the low bine density medications is bisphosphonates.
In the fifth year of the ongoing trial, all participants were asked to complete a supplemental questionnaire, which included questions about their use of medications that treat thinning bones.
A total of 29,254 women were included in the analysis, for which 115 endometrial cancers have been diagnosed since the completion of the questionnaires.
The rate of endometrial cancer among women who had taken bisphosphonates was approximately half that of women who had never taken the medication (9.6 vs. 18.7 per 10,000 person years). The effect was more significant with less-aggressive cancers, according to the research.
Alford will present the study March 24 at the Society of Gynecologic Oncology's 2012 Annual Meeting on Women's Cancer in Austin, Texas.
Henry Ford researchers used data from the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian Screening Trial, which collected data on all cancer outcomes for trial participants.
At the time the women were recruited for the trial, they ranged from 55 to 70 years old.
Women with missing information on bone medication use were excluded. Only women who had not had a hysterectomy were included in the analysis.
Women without a cancer diagnosis at the time of the questionnaire were separated into groups: those who reported current or past use of a bisphosphonate and women who had never used such medications.
The study alone would not change clinical practice, and more study is necessary, according to Alford.
"This was a retrospective study, with self-reported data," cautioned Alford. "A clinical trial, with closely monitored data, needs to be done for definitive results."
The research was funded by the National Cancer Institute and Henry Ford Health System.